Shares of Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF) have received an average recommendation of “Hold” from the seven analysts that are covering the company, Marketbeat reports. Two analysts have rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company.

Separately, Zacks Investment Research cut shares of Hikma Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, November 10th.

Hikma Pharmaceuticals (OTCMKTS:HKMPF) opened at $14.00 on Friday. Hikma Pharmaceuticals has a 1-year low of $12.40 and a 1-year high of $27.50.

ILLEGAL ACTIVITY NOTICE: “Hikma Pharmaceuticals Plc (HKMPF) Given Average Rating of “Hold” by Brokerages” was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://theolympiareport.com/2017/12/24/hikma-pharmaceuticals-plc-hkmpf-given-average-rating-of-hold-by-brokerages.html.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.